The whip-smart Republican is one of the richest thirty-somethings in America. Unlike Donald Trump, he’s entirely self-made.
Category: Editors’ Pick
InnovationRx: Babylon Files For Bankruptcy
InnovationRx is your weekly digest of healthcare news. Sign up!
Next Billion-Dollar Startups 2023: AI And Data Dominate This Year’s List
The market’s obsession with data science and artificial intelligence is reflected in this year’s list of 25 companies we think most likely to reach $1 billion valuation.
This Scientist Thinks You Should Pay $215 A Month For ‘Good’ Bacteria To Help Control Your Diabetes
Biotech researcher Colleen Cutcliffe designed probiotics to help diabetics lower their blood sugar. Now she’s got a handful of expensive supplements for sale — and Halle Berry on board to help sell them.
Next Billion-Dollar Startups 2023
There are more than 50,000 venture-backed startups in the U.S., and only the tiniest fraction will ever reach a $1 billion valuation. Here are the 25 we think most likely to succeed.
Babylon ‘Winding Down’ Operations In Rwanda, Potentially Disrupting Care For 2.8 Million People
The company has received more than $2.2 million in grant funding from the Bill & Melinda Gates Foundation for its Rwanda program.
InnovationRx: 70% Of U.S. Adults ‘Concerned’ About AI In Healthcare
InnovationRx is your weekly digest of healthcare news. Sign up!
Digital Health Company Babylon Shutters U.S. Business, Lays Off Employees
The troubled virtual care firm, which has been looking for a buyer, told the Texas Workforce Commission it would “permanently close” its Austin headquarters as of August 7.
Truepill’s Sid Viswanathan Out As CEO As Troubles Mount At Tech-Enabled Pharmacy
Not quite 18 months after being named CEO of Truepill, cofounder Sid Viswanathan is gone. The company, worth $1.6 billion at its last equity funding round, faces an uncertain future with a cash squeeze and DEA investigation.
This Startup Just Raised $26 Million To Develop Safer Gene Editing Tools
By targeting RNA rather than DNA, Amber Bio aims to treat multiple genetic diseases with fewer safety risks.
